Competing Interest: Mark Lee and F.L. Baehner are employees of Genomic Health, Inc.
Genomic signatures of cancer: Basis for individualized risk assessment, selective staging and therapy†
Article first published online: 7 APR 2011
Copyright © 2011 Wiley-Liss, Inc.
Journal of Surgical Oncology
Special Issue: The Pivotal Role of the Lymphovascular System in Cancer Metastasis
Volume 103, Issue 6, pages 563–573, 1 May 2011
How to Cite
Baehner, F. L., Lee, M., Demeure, M. J., Bussey, K. J., Kiefer, J. A. and Barrett, M. T. (2011), Genomic signatures of cancer: Basis for individualized risk assessment, selective staging and therapy. J. Surg. Oncol., 103: 563–573. doi: 10.1002/jso.21838
- Issue published online: 7 APR 2011
- Article first published online: 7 APR 2011
- Manuscript Accepted: 24 NOV 2010
- Manuscript Received: 18 NOV 2010
- gene expression array;
- breast cancer;
- colon cancer;
- adrenal cancer;
The development of DNA microarray and quantitative real-time polymerase chain reaction technologies has allowed for precise quantitation of RNA expression of hundreds to thousands of genes. These technologies have significantly impacted the study and understanding of cancer in terms of its molecular and genetic characteristics. In this review article, breast cancer, colon cancer, and adrenal carcinoma have been chosen to illustrate the principle and techniques of genomic profiling and to illustrate how such methods may be used to develop genomic signatures for personalized risk assessment and to individualize patient treatment. J. Surg. Oncol. 2011;103:563–573. © 2011 Wiley-Liss, Inc.